Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Soleno Therapeutics Inc SLNO

Healthcare Biotechnology
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3... see more

Recent & Breaking News (NDAQ:SLNO)

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire 19 hours ago

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

GlobeNewswire 1 day ago

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

GlobeNewswire 13 days ago

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 6, 2024

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire October 28, 2024

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

GlobeNewswire October 21, 2024

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

GlobeNewswire October 8, 2024

Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference

GlobeNewswire September 16, 2024

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

GlobeNewswire August 27, 2024

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 19, 2024

Soleno Therapeutics Announces Updates to its Board of Directors

GlobeNewswire August 15, 2024

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 7, 2024

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

GlobeNewswire June 28, 2024

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 24, 2024

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Long-Term Investors to Contact the Firm

Accesswire June 11, 2024

Soleno Therapeutics Set to Join Russell 3000® Index

GlobeNewswire June 4, 2024

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

GlobeNewswire May 22, 2024

Soleno Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire May 22, 2024

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

GlobeNewswire May 15, 2024

INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the Firm

Accesswire May 10, 2024